Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

NEEDHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
October 14, 2025 08:10 ET | Source: Candel Therapeutics

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

$50 million drawn down at closing, with access to up to an additional $80 millionStrengthens Company’s financial position; enables initiation of phase 3 clinical trial of CAN-2409 in non-small cell...
August 28, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
August 14, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Presented positive results from the phase 3 randomized, placebo-controlled clinical trial of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer, during an oral presentation at the 2025...
July 30, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

NEEDHAM, Mass., July 30, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
July 09, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

NEEDHAM, Mass., July 09, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
May 27, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

NEEDHAM, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal...
May 22, 2025 17:05 ET | Source: Candel Therapeutics

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...
May 13, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

Announced accepted oral presentation of positive phase 3 randomized placebo controlled clinical trial results of CAN-2409 (aglatimagene besadenovec) in localized prostate cancer at the 2025 American...
May 06, 2025 08:05 ET | Source: Candel Therapeutics

Candel Therapeutics to Present at Upcoming Investor Conferences

NEEDHAM, Mass., May 06, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal...